Results 241 to 250 of about 1,417,591 (372)

Commercial Health Plan Coverage of Selected Treatments for Opioid Use Disorders from 2003 to 2014 [PDF]

, 2017
Sharon Reif, Timothy B. Creedon, Constance M. Horgan, Maureen T. Stewart, Deborah W. Garnick   +4 more
openalex   +1 more source

Steroids for Pediatric Adenotonsillectomy Pain—A Prospective Multicenter Randomized Trial

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective To compare postoperative caregiver‐reported pain control of two steroid regimens following pediatric adenotonsillectomy. Secondary objectives assessed differences in analgesic use, return to normal diet, caregiver calls, adverse effects, and emergency room (ER) visits. Study Design Prospective randomized pragmatic trial.
Kevin D. Pereira, Wiktoria A. Gocal, Anna V. Borodianski, Mary E. Williamson, Hengameh K. Behzadpour, Sonal Saraiya, Diego A. Preciado, Amal Isaiah   +7 more
wiley   +1 more source

A rational approach to opioid use disorder in primary care [PDF]

, 2017
Daniel G. Tobin
openalex   +1 more source

Treatment Experience Using a Micro‐Induction Buprenorphine Protocol for Chronic Pain in Pediatric Sickle Cell Disease

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Patients with sickle cell disease (SCD) experience painful vaso‐occlusive episodes that increase with age; a subset develops chronic pain (CP). CP is usually managed with acute pain management guidelines despite evidence of ineffectiveness.
Ashwin Patel, Grace Kalmus, Carlton Dampier, Ifeyinwa Osunkwo, Tamara New, Beatrice Gee, Elna Saah   +6 more
wiley   +1 more source

Race/ethnicity moderates the associations between lifetime psilocybin use and opioid use disorder. [PDF]

PLoS One
Jones G.
europepmc   +1 more source

Medication Utilization Among Children With Sickle Cell Disease in the United States

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background and Objective The medication management of children with sickle cell disease (SCD), especially since the release of the 2014 National Heart, Lung, and Blood Institute (NHLBI) SCD treatment guidelines, is not well described in the published literature.
Abiodun John Ologunowa, Kelly L. Matson, Jung Eun Lee, Meghan McCormick, Mary L. Greaney, Aisling R. Caffrey   +5 more
wiley   +1 more source

Pain as a Predictor for Opioid Use Disorder [PDF]

, 2017
Xiulu Ruan, Srinivas Chiravuri, Alan D. Kaye   +2 more
openalex   +1 more source

Relationship of the revised anticholinergic drug scale with cultured cell‐based serum anticholinergic activity and cognitive measures in older adults with mild cognitive impairment or remitted depression

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView.
Abstract Objective The Anticholinergic Drug Scale (ADS) is a commonly used measure of anticholinergic exposure. This study describes an expanded and revised version of the ADS (rADS) and its relationship with cultured cell‐based serum anticholinergic activity (cSAA) and cognitive measures.
Ryan M. Carnahan, Susmita Chandramouleeshwaran, Naba Ahsan, Roger Raymond, Jose N. Nobrega, Wei Wang, Corinne E. Fischer, Alastair J. Flint, Nathan Herrmann, Sanjeev Kumar, Krista L. Lanctôt, Linda Mah, Benoit H. Mulsant, Bruce G. Pollock, Tarek K. Rajji   +14 more
wiley   +1 more source

Forging hospital and community partnerships to enable care coordination for opioid use disorder. [PDF]

Addict Sci Clin Pract
Lindenfeld Z, Franz B, Lai AY, Pagán JA, Fenstemaker C, Cronin CE, Chang JE.   +6 more
europepmc   +1 more source

(240) Psychological flexibility and chronic pain characteristics in patients seeking treatment for opioid use disorder [PDF]

, 2017
Megan E. Curtis, Kristen Rosen, Jennifer Sharpe Potter   +2 more
openalex   +1 more source